KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Operating Expenses: 2011-2025

Historic Other Operating Expenses for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Sep 2025 value amounting to $43.3 million.

  • Supernus Pharmaceuticals' Other Operating Expenses rose 20.07% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 1.86%. This contributed to the annual value of $149.8 million for FY2024, which is 18.97% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Other Operating Expenses is $43.3 million, which was up 14.99% from $37.6 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Other Operating Expenses high stood at $60.7 million for Q4 2023, and its period low was $22.0 million during Q1 2021.
  • Moreover, its 3-year median value for Other Operating Expenses was $41.8 million (2023), whereas its average is $41.7 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 306.08% in 2021, then declined by 26.34% in 2024.
  • Supernus Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $30.1 million in 2021, then skyrocketed by 36.86% to $41.2 million in 2022, then spiked by 47.11% to $60.7 million in 2023, then decreased by 26.34% to $44.7 million in 2024, then increased by 20.07% to $43.3 million in 2025.
  • Its Other Operating Expenses was $43.3 million in Q3 2025, compared to $37.6 million in Q2 2025 and $43.2 million in Q1 2025.